keyword
MENU ▼
Read by QxMD icon Read
search

mCRC

keyword
https://www.readbyqxmd.com/read/29155929/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with-metastatic-colorectal-cancer-a-jsmo-esmo-initiative-endorsed-by-csco-kaco-mos-sso-and-tos
#1
T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis, K Yamazaki, R-H Xu, T W Kim, F Ismail, I B Tan, K-H Yeh, A Grothey, S Zhang, J B Ahn, D Chong, L-T Chen, S Kopetz, T Eguchi-Nakajima, H Ebi, A Ohtsu, A Cervantes, K Muro, J Tabernero, H Minami, F Ciardiello, J-Y Douillard
The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting...
November 16, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29155512/efficacy-and-safety-of-cetuximab-plus-folfox-in-second-line-and-third-line-therapy-in-metastatic-colorectal-cancer
#2
Ersin Ozaslan, Ulas Serkan Topaloglu, Mevlude Inanc, Umut Gokmen Erdem, Hacer Demir, Erkan Arpaci, Mehmet Metin Seker, Mustafa Karaagac, Melih Kiziltepe, Baki Eker, Metin Ozkan
PURPOSE: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. METHODS: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were alsï given irinïtecan and/ïr ïxaliplatin cïmbined with fluorïpyrimidine±bevacizumab. Tumor respïnse and survival were evaluated using RECIST and Kaplan-Meier methïd respectively...
July 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29153430/real-world-effect-of-maintenance-and-intermittent-chemotherapy-on-survival-in-metastatic-colorectal-cancer
#3
Jonathan M Loree, Sean K Tan, Laurence M Lafond, Caroline H Speers, Hagen F Kennecke, Winson Y Cheung
BACKGROUND: With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS: Using a population-based cohort of mCRC patients who received combination chemotherapy, we aimed to describe the use of IC/MC and their effect on overall survival (OS)...
October 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29152120/hierarchical-clustering-analysis-identifies-metastatic-colorectal-cancers-patients-with-more-aggressive-phenotype
#4
Giuseppina Opinto, Nicola Silvestris, Matteo Centonze, Giusi Graziano, Rosamaria Pinto, Livia Fucci, Giovanni Simone, Anita Mangia
A large percentage of metastatic colorectal cancer (mCRC) patients presents metastasis at the time of diagnosis. In the last years, great efforts have been made in the treatment of these patients with the identification of different phenotypes playing a key role in the definition of new systemic therapies. Unsupervised hierarchical clustering analysis (HCA) was performed considering the clinicopathological characteristics of 51 mCRCs. Using immunohistochemistry on tissue microarrays, we assessed the expression of β-catenin, NHERF1, RASSF1A, TWIST1, HIF-1α proteins in tumors and paired liver metastases...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29145602/genotype-based-selection-of-treatment-for-patients-with-advanced-colorectal-cancer-seticc-a-pharmacogenetic-based-randomized-phase-ii-trial
#5
A Abad, E Martínez-Balibrea, J M Viéitez, V A Orduña, P García Alfonso, J L Manzano, B Massutí, M Benavides, A Carrato, M Zanui, J Gallego, C Grávalos, V Conde, M Provencio, M Valladares, R Salazar, J Sastre, C Montagut, F Rivera, E Aranda
Background: There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3' untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy for patients with mCRC. Patients and methods: This randomized, open-label phase II trial compared bevacizumab plus XELOX (control) versus treatment tailored according to TYMS-3'UTR 6 bp ins/del and ERCC1-118C/T polymorphisms...
November 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29140155/persistent-prevention-of-oxaliplatin-induced-peripheral-neuropathy-using-calmangafodipir-pledox-%C3%A2-a-placebo-controlled-randomised-phase-ii-study-pliant
#6
Bengt Glimelius, Nebojsa Manojlovic, Per Pfeiffer, Baadur Mosidze, Galina Kurteva, Mia Karlberg, Devalingam Mahalingam, Peter Buhl Jensen, Jan Kowalski, Marie Bengtson, Malin Nittve, Jacques Näsström
PURPOSE: Oxaliplatin causes disabling acute and chronic peripheral neuropathy. We explored the preventive effects of calmangafodipir, mimicking the mitochondrial enzyme manganese superoxide dismutase, thereby protecting cells from oxidative stress, in a placebo-controlled, double-blinded randomised phase II study (ClinicalTrials.gov.NCT01619423) in patients with metastatic colorectal cancer (mCRC). PATIENT AND METHODS: mCRC patients treated with modified FOLFOX-6 (folinic acid 200 mg/m(2), 5-fluorouracil bolus 400 mg/m(2), oxaliplatin 85 mg/m(2) and 5-fluorouracil 2400 mg/m(2) continuous infusion for 46 h) every fortnight for 8 cycles in first or second line were eligible...
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29138376/-the-changes-in-the-neutrophil-to-lymphocyte-ratio-can-predict-the-timing-of-chemotherapeutic-regimen-alteration-in-patients-with-metastatic-colorectal-cancer
#7
Katsuki Muneoka, Yoshio Shirai, Masataka Sasaki, Shinsuke Honma, Jun Sakata, Junkichi Kanda, Hiroyuki Wakabayashi, Toshifumi Wakai
AIM: In order to determine if the changes in the neutrophil-to-lymphocyte ratio(NLR)can predict the timingof regimen alteration, the outcome of chemotherapy for metastatic colorectal cancer was analyzed retrospectively. METHODOLOGY: Thirty patients with unresectable metastatic colorectal cancer were administered chemotherapy from January 2005 to December 2015 at the Niitsu Medical Center Hospital. The NLR was calculated from complete blood counts obtained prior to administration of chemotherapy and at the time of the best response...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29136952/identification-and-validation-of-cetuximab-resistance-associated-long-noncoding-rna-biomarkers-in-metastatic-colorectal-cancer
#8
Ke Peng, Ruiqi Liu, Yiyi Yu, Li Liang, Shan Yu, Xiaojing Xu, Tianshu Liu
BACKGROUND: Cetuximab is one of the most widely used epidermal growth factor receptor (EGFR) inhibitors to treat patients with metastatic colorectal cancer (mCRC) harboring wild-type of RAS/RAF status. However, primary and acquired resistance to cetuximab is often found during target therapy. METHODS: To gain insights into the functions of long non-coding RNA (lncRNA) in cetuximab resistance, we used a lncRNA-mining approach to distinguish lncRNA specific probes in Affymetrix HG-U133A 2...
November 10, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29134439/treatment-related-survival-associations-of-claudin-2-expression-in-fibroblasts-of-colorectal-cancer
#9
Artur Mezheyeuski, Carina Strell, Ina Hrynchyk, Tormod Kyrre Guren, Anca Dragomir, Tatyana Doroshenko, Oksana Pashkova, Julia Gorgun, Kseniya Ruksha, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, David Edler, Anna Martling, Bengt Glimelius, Arne Östman, Anna Portyanko
Claudin-2 is a trans-membrane protein-component of tight junctions in epithelial cells. Elevated claudin-2 expression has been reported in colorectal cancer (CRC). The aim of this study was to investigate the expression patterns of claudin-2 in human CRC samples and analyze its association with clinical characteristics and treatment outcome. TMAs of primary tumors from two cohorts of metastatic CRC (mCRC) were used. Claudin-2 IHC staining was evaluated in a semi-quantitative manner in different regions and cell types...
November 13, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29133190/integrating-geriatric-assessment-in-the-first-line-chemotherapy-treatment-in-older-patients-with-metastatic-colorectal-cancer-results-of-a-prospective-observational-cohort-study-avaplus
#10
Lore Decoster, Cindy Kenis, Benedicte Naessens, Ghislain Houbier, Marc De Man, Guy Lambrecht, Els Monsaert, Veerle Moons, Philippe Vergauwe, Hans Prenen, Eric Van Cutsem, Hans Wildiers
OBJECTIVES: This study aims to investigate the use of chemotherapy with or without bevacizumab in older patients with metastatic colorectal cancer (mCRC) in current daily practice and to identify predictive parameters for treatment-related outcomes. PATIENTS AND METHODS: This is a Belgian multi-centre, observational cohort study. Patients≥70years old with mCRC considered suitable for first-line chemotherapy were eligible for inclusion. At baseline geriatric screening and assessment was performed...
November 10, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29129559/treatment-and-survival-outcome-of-braf-mutated-metastatic-colorectal-cancer-a-retrospective-matched-case-control-study
#11
Hamzeh Kayhanian, Emily Goode, Francesco Sclafani, Joo Ern Ang, Marco Gerlinger, David Gonzalez de Castro, Scott Shepherd, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling
BACKGROUND: Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAF-mutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group. PATIENTS AND METHODS: All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified...
October 16, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29128267/clinical-relevance-of-alternative-endpoints-in-colorectal-cancer-first-line-therapy-with-bevacizumab-a-retrospective-study
#12
Anthony Turpin, Sophie Paget-Bailly, Anne Ploquin, Antoine Hollebecque, Charlotte Peugniez, Farid El-Hajbi, Franck Bonnetain, Mohamed Hebbar
BACKGROUND: We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab. PATIENTS AND METHODS: We assessed OS, progression-free survival (PFS), duration of disease control (DDC), the sum of the periods in which the disease did not progress, and the time to failure of strategy (TFS), which was defined as the entire period before the introduction of a second-line treatment...
October 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29123263/nuclear-igf-1r-predicts-chemotherapy-and-targeted-therapy-resistance-in-metastatic-colorectal-cancer
#13
Jordi Codony-Servat, Miriam Cuatrecasas, Elena Asensio, Carla Montironi, Anna Martínez-Cardús, Mercedes Marín-Aguilera, Carlos Horndler, Eva Martínez-Balibrea, Michele Rubini, Pedro Jares, Oscar Reig, Iván Victoria, Lydia Gaba, Marta Martín-Richard, Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, Jaime Feliu, Jose Carlos Méndez, Miguel Méndez, Javier Gallego, Antonieta Salud, Federico Rojo, Antoni Castells, Aleix Prat, Rafael Rosell, Xabier García-Albéniz, Jordi Camps, Joan Maurel
BACKGROUND: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. METHODS: We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients...
November 9, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29123255/clinicopathological-factors-influencing-outcome-in-metastatic-colorectal-cancer-patients-treated-with-fluoropyrimidine-and-bevacizumab-maintenance-treatment-vs-observation-an-individual-patient-data-meta-analysis-of-two-phase-3-trials
#14
Kaitlyn K H Goey, Sjoerd G Elias, Axel Hinke, Martijn G H van Oijen, Cornelis J A Punt, Susanna Hegewisch-Becker, Dirk Arnold, Miriam Koopman
BACKGROUND: The CAIRO3 and AIO 0207 trials demonstrated the efficacy of fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment in metastatic colorectal cancer (mCRC) patients. In this individual patient data meta-analysis with updated follow-up, we aim to provide more precise estimates of treatment effects and to identify subgroups that benefit most from maintenance treatment or observation. METHODS: In 871 patients, randomised to FP+Bev maintenance treatment or observation, we investigated whether treatment effect was modified by sex, age, performance status, response to induction treatment, primary tumour location, number of metastatic sites, disease stage and primary tumour resection, serum LDH, platelet count, CEA, and RAS/BRAF mutation status...
November 9, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29115932/prognostic-and-clinicopathological-significance-of-circulating-tumor-cells-detected-by-rt-pcr-in-non-metastatic-colorectal-cancer-a-meta-analysis-and-systematic-review
#15
Chaogang Yang, Kun Zou, Liang Zheng, Bin Xiong
BACKGROUND: Circulating tumor cells (CTCs) have been accepted as a prognostic marker in patients with metastatic colorectal cancer (mCRC, UICC stage IV). However, the prognostic value of CTCs in patients with non-metastatic colorectal cancer (non-mCRC, UICC stage I-III) still remains in dispute. A meta-analysis was performed to investigate the prognostic significance of CTCs detected by the RT-PCR method in patients diagnosed with non-mCRC patients. METHODS: A comprehensive literature search for relevant articles was performed in the EmBase, PubMed, Ovid, Web of Science, Cochrane library and Google Scholar databases...
November 7, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29113730/conversion-to-resection-in-patients-receiving-systemic-chemotherapy-for-unresectable-and-or-metastatic-colorectal-cancer-predictive-factors-and-prognosis
#16
Hiroaki Nozawa, Soichiro Ishihara, Kazushige Kawai, Keisuke Hata, Tomomichi Kiyomatsu, Toshiaki Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Kazuhito Sasaki, Manabu Kaneko, Koji Murono
BACKGROUND: Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases remain largely unknown. PATIENTS AND METHODS: We reviewed the data from metastatic CRC (mCRC) patients who had received oxaliplatin- or irinotecan-based systemic chemotherapy from 2005 to 2016...
October 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29113675/surgery-induced-tumor-growth-in-metastatic-colorectal-cancer
#17
REVIEW
Klaas M Govaert, Jennifer M J Jongen, Onno Kranenburg, Inne H M Borel Rinkes
Metastatic colorectal cancer (mCRC) is a devastating disease causing 700.000 deaths annually worldwide. Metastases most frequently develop in the liver. Partial hepatectomy has dramatically improved clinical outcome and is the only curative treatment option for eligible patients with mCRC. Pre-clinical studies have shown that surgical procedures can have tumor-promoting local 'side-effects' such as hypoxia and inflammation, thereby altering the behaviour of residual tumor cells. In addition, systemically released factors following (colon or liver) surgery can act as a wakeup-call for dormant tumor cells in distant organs and/or help establish a pre-metastatic niche...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29111094/real-time-pcr-based-method-for-the-rapid-detection-of-extended-ras-mutations-using-bridged-nucleic-acids-in-colorectal-cancer
#18
Takao Iida, Yukie Mizuno, Yasuharu Kaizaki
Mutations in RAS and BRAF are predictors of the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). Therefore, simple, rapid, cost-effective methods to detect these mutations in the clinical setting are greatly needed. In the present study, we evaluated BNA Real-time PCR Mutation Detection Kit Extended RAS (BNA Real-time PCR), a real-time PCR method that uses bridged nucleic acid clamping technology to rapidly detect mutations in RAS exons 2-4 and BRAF exon 15...
October 27, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29110922/cost-effectiveness-of-trifluridine-tipiracil-for-previously-treated-metastatic-colorectal-cancer-in-england-and-wales
#19
Ash Bullement, Stuart Underhill, Ronan Fougeray, Anthony James Hatswell
BACKGROUND: Treatment options at third-line and beyond for patients with late-line metastatic colorectal cancer (mCRC) are limited, and outcomes are poor with best supportive care (BSC). This study investigated the cost-effectiveness of trifluridine/tipiracil and regorafenib relative to BSC alone in patients with mCRC who have been previously treated with, or are not considered candidates for, standard chemotherapies. MATERIALS AND METHODS: A partitioned survival model was constructed to assess the lifetime costs and benefits accrued by patients...
September 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29108355/a-phase-i-clinical-trial-of-binimetinib-in-combination-with-folfox-in-patients-with-advanced-metastatic-colorectal-cancer-who-failed-prior-standard-therapy
#20
May Cho, Jun Gong, Paul Frankel, Timothy W Synold, Dean Lim, Vincent Chung, Joseph Chao, Daneng Li, Yuan Chen, Stephen Sentovich, Kurt Melstrom, Gagandeep Singh, Eloise Luevanos, Marwan Fakih
Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment...
October 3, 2017: Oncotarget
keyword
keyword
37091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"